Damora Therapeutics Inc(GLTO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -12.1 | Insider Own | 7.63% | Shs Outstand | 60.2M | Perf Week | -4.53% |
| Market Cap | 1.73B | Forward P/E | - | EPS next Y | -11.96% | Insider Trans | -0.02% | Shs Float | 55.6M | Perf Month | 26.78% |
| Enterprise Value | 1.72B | PEG | - | EPS next Q | -0.11 | Inst Own | 16.1% | Short Float | 0.5% | Perf Quarter | 25.34% |
| Income | -0.02B | P/S | - | EPS this Y | 94.84% | Inst Trans | 1.75% | Short Ratio | 1.56 | Perf Half Y | 853.16% |
| Sales | 0.00B | P/B | 5.71 | EPS next 5Y | 56.9% | ROA | -92.89% | Short Interest | 0.28M | Perf YTD | 24.68% |
| Book/sh | 5.02 | P/C | 227.11 | EPS past 3/5Y | 28.75% 14.83% | ROE | -114.81% | 52W High | -25.14% ($38.33) | Perf Year | 606.65% |
| Cash/sh | 0.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | -196.48% | 52W Low | 1327.36% ($2.01) | Perf 3Y | -40.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.42% | Gross Margin | - | Volatility(W/M) | 9.28% 11.03% | Perf 5Y | -88.51% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.86 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.73 | EPS Q/Q | 30.38% | Profit Margin | - | RSI (14) | 51.68 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.73 | Sales Q/Q | - | SMA20 | -0.09% ($28.72) | Beta | 1.57 | Target Price | $46.75 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2025/11/6 | SMA50 | 8.59% ($26.42) | Rel Volume | 1.31 | Prev Close | $28.91 |
| Employees | 5 | LT Debt/Eq | 0.21 | EPS/Sales Surpr. | - | SMA200 | 120.73% ($13) | Avg Volume(3M) | 0.18M | Price | $28.69 |
| IPO | 2020/10/29 | Option/Short | No/Yes | Trades | 4132 | Volume | 231,433 | Change | -0.76% |
🧬 This is a US clinical-stage biotech company developing blood cancer therapies. It is developing antibody therapeutics targeting blood disorders such as myeloproliferative neoplasms caused by specific gene mutations, and holds a leading early-clinical-stage candidate along with a well-funded balance sheet. Formerly known as Galecto, it has rebranded as a blood cancer antibody biotech, and its stock performance is heavily dependent on clinical progress.
Over the past 1 year, roughly in the middle
25% below its 1-year high.
Traded more than usual. That is 131% of its average volume.
GLTO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +94.8% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.5%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 16.1%.
Tap to view numbers
It ranks #114 of 598 in the industry
Based on market cap of $2B.
BRVE#111 Braveheart Bio Inc $2B PER - 
SRPT#112 Sarepta Therapeutics Inc $2B PER - 
NRIX#113 Nurix Therapeutics Inc $2B PER 6.9 GLTO#114 Damora Therapeutics Inc $2B PER - 
ABSI#114 Absci Corp $2B PER - 
FAQ
What kind of company is GLTO?
GLTO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GLTO?
The market cap of GLTO is approximately $1.7B, ranking 2,133 within its sector.
What is the 52-week high and low for GLTO?
GLTO has recorded a 52-week high of $38.33 and a low of $2.01.
